New advances in chemotherapies have offered significant improvements in cancer survival, but can often present negative side effects to the heart. Researchers are able to use Myocardial Solutions’ products like HARP® to measure subtle changes in heart function to assess the cardiotoxicity of certain chemotherapies. In addition, using our VIRTUE platform, researchers can analyze tissue characteristics and measure the extra-cellular volume (ECV) of the myocardial wall.

Relevant Papers

Olga H. Toro-Salazar, MD, Eileen Gillan, MD, Michael T. O’Loughlin, MD, Georgine S. Burke, PhD, Joanna Ferranti, MPH, Jeffrey Stainsby, MSc, Bruce Liang, MD, Wojciech Mazur, MD, Subha V. Raman, MD, MSEE and Kan N. Hor, MD. Occult Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy. Circulation: Cardiovascular Imaging.
2013; 6: 873-880

Contact Us

We work with Medical Research Centers, MRI Manufacturers,
Outpatient Imaging Centers and Physicians

Myocardial Solutions' technology has been used globally in over 70 major medical research centers and is established as the gold standard for strain measurement. The research has yielded over 250 articles in peer-reviewed journals (50 articles from Circulation and JACC alone) that validate CMR strain testing. MyoStrain’s predecessor software (HARP & VIRTUE) have 510(k) clearance and CE Mark certification.
MyoStrain has CE mark certification, and Myocardial Solutions is actively pursuing FDA 510(k) clearance for MyoStrain.